



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

St. Paul's Hospital
613-1081 Burrard Street
Vancouver, BC
Canada V6Z 1Y6

Tel 604.806.8477
Fax 604.806.8464
www.cfenet.ubc.ca

March 3, 2017

RE:

Emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (Descovy™ 200/10mg)
Emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 25 mg (Descovy™ 200/25mg)

Dear Doctor:

This is to inform you that emtricitabine (FTC)/tenofovir alafenamide (TAF) is available by prescription through the BC-CfE **for patients who require continuation of tenofovir-based therapy and who have documented renal or bone toxicity to tenofovir DF (TDF)**. TAF is not currently available in the absence of documented TDF toxicity.

Under exceptional circumstances TAF requests may be considered for ARV naïve patients who have renal or bone disease at baseline. These cases will be addressed on a case by case basis by BC-CfE. Genvoya® (elvitegravir/cobicistat/FTC/TAF) is not currently available by prescription through the BC-CfE.

FTC/TAF Dosing

In accordance with the Health Canada approval, FTC/TAF should be prescribed as follows:

FTC/TAF 200/10mg – for regimens including ritonavir or cobicistat

FTC/TAF 200/25mg – for regimens without a pharmacokinetic boosting agent (i.e. with an NNRTI, integrase inhibitor, or unboosted atazanavir)

Co-administration of FTC/TAF is NOT recommended with potent p-glycoprotein inducers (e.g. rifabutin, rifampin, carbamazepine, phenytoin, St. John's Wort).

For questions re: FTC/TAF dosing, please contact the St. Paul's Hospital Ambulatory pharmacy (1-888-511-6222).

Prescribing

All new prescriptions for FTC/TAF require submission of a HIV Drug Treatment Program Prescription Request form. When requesting FTC/TAF, **please provide justification** for its use on the prescription form and **appropriate documentation** (i.e. laboratory or DXA scan results). Failure to provide appropriate justification may result in delays in processing your request.

The **specific criteria** are (must meet **both** criteria A and B):

A. Cannot take abacavir, due to HLA-B*5701 positivity, documented abacavir resistance, or documented significant abacavir intolerance

or

HBsAg positive (chronic HBV infection)

AND

B. One or more of the following conditions while receiving TDF:

- eGFR < 60 mL/min for ≥ 3 months
- Severe hypophosphatemia (serum phosphate < 0.32 mmol/L)
- Documented osteoporosis (at least one T-score ≤ -2.5 at the hip or spine on DXA scan)
- In premenopausal women and men < 50 years of age, a Z score ≤ -2.0
- Fragility fracture (atraumatic fracture or fracture resulting from minimal trauma)
- Documented osteomalacia (laboratory and/or imaging)

For questions regarding availability of FTC/TAF, please contact the St. Paul's Hospital Ambulatory pharmacy (1-888-511-6222).

Sincerely,



Julio S.G. Montaner, OC, OBC, MD, DSc (Hon), FRCPC, FCCP, FACP, FRSC
Director
BC Centre for Excellence in HIV/AIDS
St. Paul's Hospital, Providence Health Care